AMGN · 8-K · 20260804PR000124
Medicare Drug Price Setting
AMGEN INC · 2026-08-04 · Importance 68 · Surprise 84 · In source text
U.S. Medicare Part D price setting under the Inflation Reduction Act became effective for Enbrel on January 1, 2026. Amgen reported that Enbrel’s second-quarter sales declined 4% year over year to $580 million, with net selling price down 22%. The company identified the Inflation Reduction Act pricing provisions and increased 340B program mix as drivers of the lower net selling price.
Key facts
- The decline in Enbrel net selling price reflects the impact of U.S. Medicare Part D price setting under the Inflation Reduction Act, effective January 1, 2026, as well as an increased 340B Program mix. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | — | The decline in Enbrel net selling price reflects the impact of U.S. Medicare Part D price setting under the Inflation Reduction Act,… |